Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycograb in Cryptococcal Meningitis
NCT00847678Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2006
- Primary completion
- Nov 2007
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of efungumab in cryptococcal meningitis, sponsored by Novartis. Started Aug 2006; status: terminated.
02
Drugs
efungumab
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT00847678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00847678.